In the phase II KEYNOTE-158 trial, an objective response to pembrolizumab was noted in 14.3% of patients with PD-L1 positive tumors who had received > 1 prior ChT regimens for recurrent or metastatic disease [40]. The gene discussed is CD274; the disease is metastatic neoplasm.